Key result
In patients hospitalized for acute heart failure, a sodium non-excretor profile was associated with higher 1-year mortality compared to sodium excretors.
Why the study?
Does renal profiling based on eGFR and spot urine sodium identify high-risk acute heart failure patients?
Does renal profiling based on eGFR and spot urine sodium identify high-risk acute heart failure patients?
Answers are grounded in this paper and cite their sources.
Spot urine sodium measured early during diuresis is a strong predictor of 1-year mortality in acute heart failure, independent of eGFR, highlighting the prognostic value of identifying sodium non-excretors.
This article refers to ‘Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high-risk acute heart failure patients’ by J. Biegus et al., published in this issue on pages 729–739. Every era grapples with a medical riddle and the complexities underlying the interaction between heart and kidney physiology are no exception, as knowledge gaps regarding this complex interaction have persisted throughout much of medical history. Mercurial agents, which were being used since the 1500s for their diuretic properties in the treatment of ‘dropsy’, were thought to act through extra-renal pathways and it was not until the late 1920s that the mechanism was revealed as being mediated through the kidneys via decreased tubular reabsorption of filtered sodium.1, 2 Furosemide entered the scene as a ‘novel’ diuretic in the 1960s and quickly became the mainstay for decongestion and volume removal in heart failure, largely due to its favourable diuretic profile of achieving natriuresis without excessive potassium wasting.1, 3, 4 Despite significant strides in our understanding of the cardio-renal syndrome, congestion, and more precisely, persistent congestion still plagues physicians today given its implications on prognosis and adverse outcomes in acute heart failure. Inadequate decongestion is strongly tied to the phenomenon of diuretic resistance and lies at the crux of a significant proportion of heart failure readmissions.5, 6 More recently there has been increasing interest in defining what a good diuretic response is and looking beyond simply the quantity of urine output as a measure of success. Prior studies have explored alternative metrics for quantifying diuretic resistance and complex cardio-renal interactions which are not fully elucidated by traditional laboratory markers, such as serum creatinine that often rises with diuretic therapy. Notably, a change in serum creatinine, however, is not necessarily reflective of a significant (or permanent) deterioration in renal function and has not been shown to correlate with worse outcomes after adjusting for baseline degree of renal insufficiency and in the setting of brisk diuresis.7 Therefore, other more practical and precise measures of clinical assessment and stratification have been sought after. Unfortunately, diuretic dose in isolation has not consistently been shown to correlate with outcomes given that dose is influenced by multiple variables that may be independent of patient-specific factors and includes variability in physician practice.8-12 However, urinary output relative to diuretic dose, or ‘diuretic efficiency’, has been shown to be a practical surrogate of diuretic resistance, with lower diuretic efficiency being predictive of worse outcomes in heart failure.8 Several studies have shown that effective response to diuretic therapy largely rests on natriuresis and that an association exists between inadequate urine sodium excretion after diuretic administration and adverse outcomes in acute heart failure.5, 6, 13-15 This association between sodium hyper-reabsorption and prognosis in heart failure underscores the deranged renal compensatory mechanisms in the face of hypoperfusion, chronic diuretic use, and upregulation of neurohormonal systems that underlie diuretic resistance.15 However, there remains an unmet need in developing a practical and simple approach to risk stratification of heart failure patients in real-time clinical practice while leveraging the important insights put forth by prior studies regarding impaired urinary excretion of sodium (UNa) as a marker of diuretic resistance. In this issue of the Journal, Biegus et al.16 present an interesting follow-up to this issue of renal sodium handling in heart failure. The Authors conducted a prospective study of patients hospitalized for heart failure requiring intravenous loop diuretics with sequential daily sampling of blood and urine. Patients were then classified into four groups according to estimated glomerular filtration rate (eGFR) and sodium excretion, using arbitrary cutoffs of eGFR ≥60 mL/min and UNa ≥60 mmol/L to define normal values. The Authors observed that patients with preserved eGFR/sodium ‘non-excretors’ had the highest 1-year mortality (52.5%) even more so than sodium non-excretors with impaired eGFR (43.2%), followed by impaired eGFR/sodium excretors (31.9%), and preserved eGFR/sodium excretors (15.7%). Importantly, in multivariate analyses, UNa ≤60 mmol/L at day 1 and average (but not eGFR) remained an independent factor related to higher mortality. There was no observed correlation between average eGFR and average UNa; however, there was a trend for correlation between change of UNa and change of eGFR in the first 2 days. Importantly, the Authors showed that patients with a sodium non-excretor profile irrespective of eGFR experienced smaller increment improvement in dyspnoea and were at higher risk for in-hospital worsening necessitating inotrope use as well as risk for rehospitalization. Furthermore, there was no correlation between UNa and N-terminal pro-B-type natriuretic peptide (NT-proBNP) or furosemide dose. Interestingly, the combination of an impaired eGFR/sodium non-excretor profile did show clinical markers consistent with a sicker population manifested by a significantly lower blood pressure, a trend for higher NT-proBNP, and a higher rate of inotropic therapy use. This study yields several important insights. First, UNa measured early in the diuresis phase was a strong and consistent predictor of outcomes irrespective of eGFR, confirming prior observations with directly measured UNa per furosemide dose.16 As the Authors point out, this may be related to these variables capturing tubular dysfunction rather than impaired glomerular filtration. This further supports the notion that residual volume overload due to inadequate sodium excretion is an ominous sign. Second, the independent interaction between diuretic dose and UNa explains the lack of correlation between diuretic dose and outcomes in prior studies.8-12 Third, by focusing on the first 2 days of hospitalization, the authors highlighted insights gained from this ‘early decongestion phase,’ which may allow clinicians to aggressively escalate diuretic dose early on.17, 18 Whether or not early intensification of diuretic dosing with this approach can significantly impact on mortality remains to be determined.19 Despite its prospective design, there are several limitations in this study that are worth noting. The study enrolled a relatively small number of patients within each of the four groups. Secondly, some patients received intravenous diuretics in the pre-hospital setting or had intensification of oral diuretics prior to admission, which may have affected baseline UNa values. In addition, there were some patients for whom a baseline UNa level was obtained after intravenous diuretic was already administered in the emergency room. Furthermore, there was lack of a standardized protocol for diuretic dosing especially beyond the first few days as decreasing UNa is likely a necessary compensatory mechanism of diuresis (in other words, falling UNa upon reaching euvolaemic state may represent adequacy rather than inadequacy of diuresis). It is also unclear whether all patients will need serial assessment of UNa (for example, a patient who has >3 L/day of urine output is likely diuretic responsive). Nevertheless, these intriguing results highlight the potential for a simple stratification scheme that may help to provide more granular information regarding future risk, thereby providing an opportunity to enhance downstream management options. This may include identifying a subset of sodium non-excretors who would be most likely to benefit from alternative diuretic (e.g. sequential nephron blockade) or even device-based strategies.20 As Hippocrates once wrote ‘no other organ system or organ of the human body provides so much information by its excretion as does the urinary system.’ Perhaps identification of sodium non-excretors is our golden ticket to finally putting ‘dropsy’ to rest. Conflict of interest: R.K. has no relationships to disclose. W.H.W.T. is a consultant for Sequana Medical A.G., Owkin Inc, Relypsa Inc, CardiolRx Inc, and PreCardia Inc, and has received honorarium from Springer Nature for authorship/editorship and American Board of Internal Medicine for exam writing committee participation, all unrelated to the contents of this paper.
No takes yet. Share an insight, caveat, or question.
Khedraki et al. (2021) conducted an editorial in acute heart failure. Sodium non-excretor profile (UNa <60 mmol/L) vs. Sodium excretor profile (UNa ≥60 mmol/L) was evaluated on 1-year mortality. In patients hospitalized for acute heart failure, a sodium non-excretor profile was associated with higher 1-year mortality compared to sodium excretors.
Synapse has enriched 10 related papers. Consider them for comparative context: